Trial Profile
A Phase 1b, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 598 in Subjects With Obesity
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs AMG 598 (Primary) ; Liraglutide (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Amgen
- 20 Dec 2019 Status changed from active, no longer recruiting to completed.
- 15 Oct 2019 Planned End Date changed from 12 Dec 2019 to 16 Dec 2019.
- 15 Oct 2019 Status changed from recruiting to active, no longer recruiting.